A growing body of evidence suggests that patients with cancer have an increased risk of severe COVID-19 infection and related complications. As such, NANETS supports the plan for COVID-19 vaccination for patients with neuroendocrine neoplasms (NENs), including well differentiated neuroendocrine tumours (NETs) and poorly differentiated neuroendocrine carcinomas (NECs).

Read full article here

*NANETs is an American organisation so some references may not apply in the UK